• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

The Tesla of Pick-Up Trucks

Tech Letter

Rivian Automotive Inc. (RIVN), the California-based EV company, touched $153 billion in market valuation making Rivian the largest U.S. company with zero revenue.

Exuberance can take you this far, but the company will need to show investors sales after the pixie dust wears off.

I understand that part of the narrative is that this could be the next Tesla (TSLA), and back of the napkin math shows us if it is a certain percentage of Tesla going forward then it would be certain billions of dollars.

The $150 billion valuation is too fast too soon, but when traders grab a hold of this rocket, all they need to do is add a little fuel.

It does speak loudly to investors that there is excess liquidity ebbing and flowing in the financial system where a stock can go this high just based on potential.

Let’s see the damn car first!

Granted, the car looks fantastic based on internet reviews, and if they do become the Tesla of pickup trucks, then anything that means reversion in the stock will be muted.

Word on the street is that only employees are driving the truck around now and the greater public should start receiving their Rivian orders at the end of 2021 or 2022.

EV peer Lucid Group Inc. also rallied intensely closing up 24% and eclipsing the valuation of Ford in the process. Lucid is now a $91 billion company, compared to Ford’s $79 billion.

Rivian will also need to compete with the upcoming European EV behemoths with Volkswagen that is Europe’s largest automaker with about 10 million vehicle deliveries per year, making it the global number two behind Toyota Motor Corp.

Rivian’s trucks are called the R1T and an electric SUV — R1S.

They forecast annual production will hit 150,000 vehicles at its main facility by late 2023.

At one point, Rivian was worth more than almost 90% of S&P 500 companies, including stocks like Goldman Sachs Group Inc., Boeing Co., Citigroup Inc., Starbucks Corp.

Rivian also benefited from Tesla’s Founder Elon Musk selling big tranches of stock which gave EV investors the green light to pile into Rivian even if it’s not for the long term.

Pricing for Rivian’s models starts around $70,000, and each features a base driving range of more than 300 miles on a full charge.

The hope is that mass affluent truck shoppers won’t be able to get enough of Rivian. Remember, the Ford F-150 is the best-selling vehicle in the country. In fact, the top six automobiles in the U.S. by sales are either pickup trucks or SUVs.

Amazon’s 20% stake in the company is the stamp of approval for many investors on the fence and they have already ordered 100,000 units for delivery by the end of 2030.

I could easily see Amazon ramping up orders quickly if they like the quality of the first two models.

Whether the stock should be $150 billion with 0 sales or not, is not really the full story of Rivian.

With only a narrow snapshot of what’s really going on, the high valuation is more a story of the momentum of the market in November that has seen big tech rejuvenate.

Rivian merely just got caught up in the updraft.

I am not diminishing the company, but they will need to demonstrate consistent earnings to build those long-term holders of the stock and I do believe they can do it.

The specs of the car look and feel like a Tesla and if they can replicate 80% of the quality with their first iterations, socially, they could catch on fire and become the new hip car to the masses.

This does set the stage for a critical first earnings report where the first sales will be thoroughly dissected with a fine-tooth comb and possible offer an entry point to investors after people realize this isn’t a $150 billion company yet.

Remember that it took Tesla years to stabilize their volatile stock, and Rivian might have to go through the same right of passage to be legit.

Rivian has the potential to become the #2 behind Tesla and that’s worth $90 billion right there, it’ll be interesting to see what pans out after that.

As for buying the stock, wait for a big sell-off then slowly scale in.

 

 

rivian

 

rivian

https://www.madhedgefundtrader.com/wp-content/uploads/2021/11/rivian-truck-2.png 520 936 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-17 14:02:292021-11-23 23:46:44The Tesla of Pick-Up Trucks
Mad Hedge Fund Trader

Quote of the Day - November 17, 2021

Tech Letter

“Invention is by its very nature disruptive. If you want to be understood at all times, then don’t do anything new.” – Said Founder and CEO of Amazon Jeff Bezos

https://www.madhedgefundtrader.com/wp-content/uploads/2021/11/jeff-bezos.png 480 266 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-17 14:00:402021-11-17 14:47:42Quote of the Day - November 17, 2021
Mad Hedge Fund Trader

November 17, 2021

Diary, Newsletter, Summary

Global Market Comments
November 17, 2021
Fiat Lux

Featured Trade:

(HOW TO HANDLE THE FRIDAY, NOVEMBER 19 OPTIONS EXPIRATION),
(GS), (MS), (BAC), (TLT), (ROM), (BRKB)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-17 09:04:112021-11-17 14:32:04November 17, 2021
Mad Hedge Fund Trader

How to Handle the Friday November 19 Options Expiration

Diary, Newsletter, Research

Happy and newly enriched followers of the Mad Hedge Fund Trader Alert Service have the good fortune to own a record ten deep-in-the-money options positions that expire on Friday, November 19 at the stock market close in two days.

I have to admit that I traded like a Wildman this month, pedal to the metal, and 100% invested. This will take our 2021 year-to-date performance to over 100% for the first time in our 14-year history. I like to think that is the end result of my 53 years of investment in researching trading strategies.

Sometimes, overconfidence works.

It is therefore time to explain to the newbies how to best maximize their profits.

These involve the:

(GS) 11/$330-$350 call spread                    10.00%

(GS) 11/$385-$395 call spread                    10.00%

(MS) 11/$85-$90 call spread                        10.00%

(MS) 11/$95-$98 call spread                        10.00%

(BAC) 11/$37-$40 call spread                      10.00%

(BAC) 11/$43-$46 call spread                      10.00%

(TLT) 11/$150-$153 put spread                    10.00%

(ROM) 11/$105-$110 call spread                 10.00%

(BRKB) 11/$275-$280 call spread               10.00%

(BRKB) 11/$277.50-$282.50 call spread     10.00%

Provided that we don’t have another 2,000-point move down in the market in the next two days, these positions should expire at their maximum profit points.

So far, so good.

I’ll do the math for you on our deepest in-the-money position, the Goldman Sachs (GS) November 19 $330-$350 vertical bull call spread, which I almost certainly will run into expiration. Your profit can be calculated as follows:

Profit: $20.00 expiration value - $16.50 cost = $3.50 net profit

(6 contracts X 100 contracts per option X $3.50 profit per options)

= $2,100 or 17.65% in 24 trading days.

Many of you have already emailed me asking what to do with these winning positions.

The answer is very simple. You take your left hand, grab your right wrist, pull it behind your neck, and pat yourself on the back for a job well done.

You don’t have to do anything.

Your broker (are they still called that?) will automatically use your long position to cover your short position, canceling out the total holdings.

The entire profit will be credited to your account on Monday morning November 22 and the margin freed up.

Some firms charge you a modest $10 or $15 fee for performing this service.

If you don’t see the cash show up in your account on Monday, get on the blower immediately and make your broker find it.

Although the expiration process is now supposed to be fully automated, occasionally machines do make mistakes. Better to sort out any confusion before losses ensue.

If you want to wimp out and close the position before the expiration, it may be expensive to do so. You can probably unload them pennies below their maximum expiration value.

Keep in mind that the liquidity in the options market understandably disappears, and the spreads substantially widen, when a security has only hours, or minutes until expiration on Friday, November 19. So, if you plan to exit, do so well before the final expiration at the Friday market close.

This is known in the trade as the “expiration risk.”

One way or the other, I’m sure you’ll do OK, as long as I am looking over your shoulder, as I will be, always. Think of me as your trading guardian angel.

I am going to hang back and wait for good entry points before jumping back in. It’s all about keeping that “Buy low, sell high” thing going.

I’m looking to cherry-pick my new positions going into the next month end.

Take your winnings and go out and buy yourself a well-earned dinner. Just make sure it’s take-out. I want you to stick around.

Well done, and on to the next trade.

 

You Can’t Do Enough Research

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/09/john-and-girls.png 322 345 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-17 09:02:182021-11-17 14:32:35How to Handle the Friday November 19 Options Expiration
Mad Hedge Fund Trader

November 16, 2021

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
November 16, 2021
Fiat Lux

Featured Trade:

(FORGOTTEN COVID-19 STOCK STILL ALIVE AND KICKING)
(GILD), (REGN), (MRNA), (AZN), (JNJ), (PFE), (BNTX), (MRK)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-16 18:02:312021-11-16 19:18:22November 16, 2021
Mad Hedge Fund Trader

Forgotten Covid-19 Stock Still Alive and Kicking

Biotech Letter

At times, it can be rewarding to go against the tide. This can also be applicable to the stock market.

Forgotten names or companies with shares that got hammered can eventually transform into remarkable investment opportunities. After all, it's always wise to invest in a quality stock when it loses some serious altitude.

Now, let's take a look at a biotechnology and healthcare business that has been performing poorly in the past 12 months but still holds a promising chance of bouncing back: Gilead Sciences (GILD).

This biotechnology giant is still reeling after its recent regulatory setback involving Filgotinib, a potential treatment for rheumatoid arthritis.

Initially, Filgotinib was slated as Gilead Sciences' next blockbuster drug. Unfortunately, the US FDA didn't agree with those plans.

The regulatory body rejected the treatment, pointing out the risks of patients developing male fertility problems as one of the significant reasons.

By November 2020, Gilead Sciences completely abandoned the Filgotinib project, at least in the United States.

Prior to this, Gilead Sciences took center stage when its Remdesivir, sold under the brand name Veklury, was identified as an effective COVID-19 treatment.

While this product has taken the back seat since other treatments from the likes of Regeneron (REGN) and especially vaccines from Moderna (MRNA), Johnson & Johnson (JNJ), AstraZeneca (AZN), Pfizer (PFE), and BioNTech (BNTX) have emerged, it still generated impressive numbers.

In the second quarter alone, Veklury brought in $829 million in revenue.

Gilead Sciences anticipate sales to reach somewhere between $2.7 billion and $3.1 billion for this drug in 2021.

Arguably, though, the biggest draw in buying Gilead Sciences stock is its HIV pipeline.

To date, the company holds roughly 75% of the market share in the US and approximately 50% in Europe.

What's even more promising is that the company's top-selling HIV product, Biktarvy, still has vast room to grow.

This is impressive considering that Biktarvy raked in approximately $2 billion in sales in the second quarter of 2021, showing off a 24.3% year-over-year jump.

Looking at its trajectory and considering that the drug generated $7.3 billion in 2020, Biktarvy sales are estimated to hit $11.7 billion in 2026.

More than the company's incredible dominance in cornering the HIV market, Gilead Sciences also has an excellent pipeline with over three dozen clinical programs queued.

Inevitably, one of its major concentrations is expanding its HIV portfolio.

In fact, it has recently teamed up with fellow biotechnology giant Merck (MRK) to collaborate on a potential HIV treatment—a candidate that's anticipated to equal if not surpass Biktarvy's fame.

One more potential blockbuster in the HIV market is Lenacapavir, which is an injection regiment that Gilead Sciences recently submitted for approval to the FDA.

If granted the green light, this will be administered once every 6 months, making it the first-ever long-acting regimen for HIV patients.

Meanwhile, the company is also growing its Hepatitis B franchise to avoid being too dependent on a single market.

So far, Gilead Sciences estimates about $1 billion in sales for this lineup in 2022, making the Hepatitis B portfolio a reliable part of the business.

Another growing section of the business is its cell therapy segment, with Yescarta and Tecartus nearing their peak performances at $1 billion in sales yearly.

Even its newly developed cancer cell therapy Magrolimab looks promising, with the potential to rake in another $1 billion in peak sales as well.

Needless to say, Gilead Sciences' new products and expansions have been displaying realistic potential to drive billions in added yearly revenue.

Overall, Gilead Sciences is a stable and profitable biotechnology and healthcare business.

It's a large-cap biopharmaceutical organization and market leader that has been solidly performing well for over 3 decades, with an influential presence in more than 35 countries.

Despite its recent challenges, Gilead Sciences remains an excellent buy, especially on the dip.

gilead sciences

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-16 18:00:372021-11-19 21:29:59Forgotten Covid-19 Stock Still Alive and Kicking
Mad Hedge Fund Trader

Trade Alert - (AMAT) November 16. 2021 - SELL-TAKE PROFITS

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-16 13:48:472021-11-16 13:51:50Trade Alert - (AMAT) November 16. 2021 - SELL-TAKE PROFITS
Mad Hedge Fund Trader

November 16, 2021

Bitcoin Letter

Mad Hedge Bitcoin Letter
November 16, 2021
Fiat Lux

Featured Trade:

(TRADERS TAKE TAPROOT PROFITS)
(BTC), (ETH)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-16 13:04:112021-11-16 16:33:32November 16, 2021
Mad Hedge Fund Trader

Traders Take Taproot Profits

Bitcoin Letter

Bitcoin (BTC) has rolled out another upgrade called Taproot — the first since 2017.

At a technical level, engineers should be in a celebratory mood because the latest upgrades always make crypto more efficient and with smoother transactions.

At the investor level, this usually serves as a liquidity event in so far as investors buy the digital gold until the upgrade and sell once the upgrade has been announced because we essentially remove the psychology of the anticipation of the new upgrade.

Removing that anticipation makes Bitcoin unattractive in the short-term, but it does no value damage to the long-term narrative.

Taproot’s new tech is coined as Schnorr signatures.

These signatures will mean transacting in Bitcoin has become more secure, efficient, and less expensive.

Most importantly, the upgrade will better enable bitcoin to execute smart contracts on the blockchain.

A critical change from Taproot is the potential for smart contracts.

Smart contracts are digital agreements written in code and stored on the blockchain.

They’re essential in powering decentralized finance, or DeFi, applications and nonfungible tokens, or NFTs.

Compared to Ethereum, Bitcoin has historically been much more limited in accommodating smart contracts.

This will likely lead to more day-to-day applications for bitcoin.

Taprooted Bitcoin will wield better security by enabling multi-signature transactions, or those that involve multiple addresses, to appear as a standard, single transaction.

Multi-signature transactions are often used to enable smart contracts.

As a result, multi-signature transactions will be indistinguishable from simple transactions translating into, meaning greater anonymity.

Schnorr signatures will limit the amount of data required for multi-signature transactions, which are more complicated to process than standard ones.

With less data involved, transactions will become more energy and time-efficient.

Consequently, transactions will be cheaper to process, leading to lower cost of transaction fees.

Taproot will effectively make the digital currency into a better all-around currency and encourage higher adoption rates.

The last major upgrade in 2017, the Lightning Network, helped facilitate much faster and cheaper bitcoin payments than before.

Clearly, the increased Bitcoin volume will take time to materialize, but the positive results from the Lightning Network is one of the main catalysts to higher Bitcoin prices that elevated to north of $60,000.

If developers can keep churning out a major upgrade every 4-5 years, it’s just a matter of time before the currency becomes frictionless, feeless, ubiquitous, and positive for the environment.

At a broader level, Bitcoin is still in the teething stages of its evolution, but it’s safe to say, it’s come a long way since its inception.

Making it more palatable for developers to create apps on will also suck away value and volume from Ether.

On the negative side of the ledger, there are a few potential drawbacks to the upgrade, but they’re minimal in the face of the benefits and only reveal themselves sometimes because Taproot is only partially adopted by network participants (only 54% of Bitcoin nodes enforce Taproot right now, a number which has ticked up in recent days).

The second negative is that it’s not entirely certain how the smart contracts and the functioning for decentralized apps (dApps) will work itself out.

Ethereum is well established on this front, and a few developers have told me that this new upgrade for the dApps and smart contract angle of it, is somewhat misleading.

It will take time to work out the kinks and not all upgrades go without issues.

As we barrel towards the launch of the Metaverse, it’s still a few years out, cryptocurrencies are basically fighting against each other to be the first of the bunch to be adopted as the payment of choice for the Metaverse.

That’s why these upgrades are highly necessary for a de facto digital arms race.

Being able to build apps on top of the crypto leads to what the Metaverse will be about.

Imagine your avatar entering the Metaverse and buying a Metaverse real estate property in Ether or Bitcoin and that transaction goes through instantaneously in real-time and 100% secure.

That is the world we are trending towards, even if we are a long way off now, and many of these developers for Ethereum and Bitcoin are skating towards where they think the puck will be in 5 or 10 years.

I believe we will hold the $58,000 support level after this dip, and we will take a run past the new all-time highs.

It’s only a matter of time before we close in on $100,000 even if traders took profits from the Taproot upgrade.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2021/11/btc.png 576 936 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-16 13:02:092021-11-16 16:33:49Traders Take Taproot Profits
Mad Hedge Fund Trader

Quote of the Day - November 16, 2021

Bitcoin Letter

“Bitcoin actually has the balance and incentives center, and that is why it is starting to take off.” – Said Julian Assange, founder of Wikileaks

https://www.madhedgefundtrader.com/wp-content/uploads/2021/11/julian-asange.png 360 286 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-11-16 13:00:052021-11-16 16:32:35Quote of the Day - November 16, 2021
Page 7 of 14«‹56789›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top